SCHEMBL1818686

SCHEMBL1818686

COc1ccc(C(=O)Cn2c(-n3ccc(N)n3)nc3ccccc32)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.59
LMNA P02545 4/20 0.59
TSHR P16473 1/20 0.59
TDP1 Q9NUW8 1/20 0.59
ALDH1A1 P00352 4/20 0.56
NPSR1 Q6W5P4 3/20 0.56
CTSD P07339 1/20 0.56
KDM4E B2RXH2 1/20 0.55
HTT P42858 1/20 0.54
MGAM O43451 1/20 0.53
AMY1A P0DUB6 1/20 0.53
GAA P10253 1/20 0.53
SI P14410 1/20 0.53
MGAM2 Q2M2H8 1/20 0.53
GSK3B P49841 1/20 0.49
POLB P06746 1/20 0.48
RAB9A P51151 1/20 0.47
TP53 P04637 1/20 0.47
RXFP1 Q9HBX9 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4996791 0.86 CXCR3 (0.57) MAPTLMNATSHRALDH1A1NPSR1
SCHEMBL5000985 0.84 SMN1; SMN2 (0.53) TSHRTDP1ALDH1A1NPSR1CTSD
SCHEMBL5000979 0.83 SMN1; SMN2 (0.45) MAPTLMNATSHRTDP1NPSR1
SCHEMBL1803118 0.80 MAPT (0.59) MAPTLMNATSHRTDP1ALDH1A1
SCHEMBL1386316 0.73 BCHE (0.68) MAPTLMNATSHRCTSDKDM4E
SCHEMBL1180378 0.69 GAA (1.00) ALDH1A1HTTMGAMAMY1AGAA
Bromide SCHEMBL29537277 0.67 MAPT (0.52) MAPTLMNATSHRTDP1ALDH1A1
SCHEMBL1800064 0.67 CTSD (0.46) MAPTLMNATSHRTDP1ALDH1A1
SCHEMBL14470429 0.67 F2R (0.61) TDP1NPSR1CTSDHTTSMN1; SMN2
SCHEMBL11262638 0.66 APEX1 (0.62) MAPTLMNATSHRTDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080287681-A1 Substituted Benzimidazoles and their Use for Inducing Apoptosis EBERLE MARTIN 2008-11-20 US claimed
US-7951957-B2 Substituted benzimidazoles and their use for inducing apoptosis BASILEA PHARMACEUTICA AG (CH) 2011-05-31 US disclosed
US-20080287681-A1 Substituted Benzimidazoles and their Use for Inducing Apoptosis EBERLE MARTIN 2008-11-20 US disclosed
US-7423157-B2 Substituted benzimidazoles and their use for inducing apoptosis BASILEA PHARMACEUTICA AG (CH) 2008-09-09 US disclosed
US-20070167505-A1 Substituted benzimidazoles and their use for inducing apoptosis BASILEA PHARMACEUTICA AG 2007-07-19 US disclosed
US-20070066670-A1 Substituted benzimidazoles and their use for inducing apoptosis BASILEA PHARMACEUTICA AG 2007-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167505-A1 Substituted benzimidazoles and their use for inducing apoptosis BAX, BCL2, BAD MAPT 4687/4885LMNA 445/4885TSHR 1194/4885
US-20070066670-A1 Substituted benzimidazoles and their use for inducing apoptosis BAX, BCL2, BAD MAPT 4687/4885LMNA 445/4885TSHR 1194/4885
US-20080287681-A1 Substituted Benzimidazoles and their Use for Inducing Apoptosis BAX, BCL2, BAD MAPT 4687/4885LMNA 445/4885TSHR 1194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.